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PENENTUAN TAHAP SERUM IL-17, IL-23 DAN RESEPTOR MEREKA 
DALAM PESAKIT SISTEMIK LUPUS ERITEMATOSUS: PERKAITAN 
DENGAN PARAMETER SEROLOGI DAN AKTIVITI PENYAKIT 
ABSTRAK 
Interleukin (IL) merupakan kumpulan sitokin, terutamanya yang disintesis 
oleh pembantu T sel CD4+, dan juga oleh sel-sel endothelial, monosit dan 
makrofaj. IL terikat pada interleukin reseptor dan bertindak sebagai salah satu faktor 
penting dalam perkembangan penyakit sistemik lupus eritematosus (SLE). Kajian ini 
bertujuan untuk menentukan tahap serum IL-17, IL-23 dan reseptor mereka; IL-
17RA dan IL-23R pada pesakit SLE berbanding dengan individu sihat. Di samping 
itu, interleukin dan reseptor mereka telah dikaitkan dengan parameter serologi dan 
aktiviti penyakit, khususnya SLEDAI-2K skor untuk menyokong hubungan IL-17, 
IL-23 dan reseptor mereka dalam patogenesis SLE. Seramai 50 pesakit SLE dan 50 
individu sihat telah diambil dalam kajian ini. Tahap serum IL-17 dan IL-23 telah 
dianalisa menggunakan antibodi spesifik ‘pre-coated’ menggunakan ujian ‘Human 
IL-17/IL-23 ELISA’. Sel darah telah diasingkan menggunakan cara ‘Histopaque-
1077 density centrifugation’ dan ditandakan dengan antibodi spesifik untuk 
pewarnaan permukaan IL-17RA dan IL-23R, dan tahap mereka ditentukan oleh 
analisis ‘flow cytometry’. Pesakit SLE menunjukkan tahap yang ketara tinggi 
daripada kedua-dua IL-17RA dan IL-23R (p<0.001) berbanding dengan individu 
sihat. Tahap signifikasi yang menurun ditunjukkan dalam IL-17 (p<0.001) manakala 
tiada perbezaan yang signifikan (p=0.73) dalam IL-23 apabila membandingkan 
dalam pesakit SLE dan individu sihat. Di samping itu, tidak ada korelasi antara tahap 
interleukin dan SLEDAI-2K dan juga parameter serologi. Menariknya, IL-17RA 
xiii 
 
mempunyai perkaitan yang ketara dengan antinuklear antibodi (ANA) (p=0.024) dan 
IL-23R mempunyai hubungkait dengan SLEDAI-2K (p=0.011). Walau 
bagaimanapun, penurunan tahap serum IL-17 mungkin perlu dikaji dengan lebih 
mendalam antara perhubungan dengan reseptornya kerana peningkatan tahap 
ekspresi IL-17RA dijangka mungkin mengambil kebanyakan serum IL-17 yang 
mengakibatkan tahap pengurangannya. Kesimpulannya, kami mencadangkan bahawa 
perencatan terapeutik pada IL-17RA dan IL-23R mungkin merupakan pilihan yang 






ELUCIDATION OF SERUM LEVELS OF IL-17, IL-23 AND THEIR 
RECEPTORS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: 
ASSOCIATIONS WITH SEROLOGICAL PARAMETERS AND DISEASE 
ACTIVITY 
ABSTRACT 
Interleukins (ILs) are a group of cytokines, mainly synthesised by CD4+ T 
helper cells, as well as by endothelial cells, monocytes and macrophages. ILs bind to 
their interleukin receptors and this is one of the pivotal factors in the development 
and progression of systemic lupus erythematosus (SLE). This study aimed to 
determine the serum levels of IL-17, IL-23 and their receptors; IL-17RA and IL-23R, 
in SLE patients compared with healthy controls. In addition, the associations of these 
interleukins and their receptors were associated with serological parameters and 
disease activity, specifically SLEDAI-2K score. SLE patients and healthy controls 
(n=50 in each group) were recruited in this study. The serum levels of IL-17 and IL-
23 were evaluated using pre-coated specific antibody via Human IL-17/IL-23 ELISA 
test. PBMCs were isolated from the peripheral blood using Histopaque-1077 density 
centrifugation and stained with fluorochrome-labelled antibodies for staining of 
surface IL-17RA and IL-23R, and their levels determined by flow cytometry 
analysis. SLE patients showed significantly elevated levels of IL-17RA and IL-23R 
(p<0.001) compared with healthy controls. Significant downregulation of serum IL-
17 (p<0.001) while no significant difference (p=0.73) in IL-23 levels were observed 
in SLE patients compared with healthy controls. In addition, no significant 
associations between IL levels with SLEDAI-2K and serological parameters. 
Interestingly, IL-17RA levels were significantly associated with antinuclear 
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antibodies (ANA) (p=0.024) and IL-23R levels were significantly associated with 
higher SLEDAI-2K scores (p=0.011). However, the decreasing level of serum IL-17 
might need further work as the relation with its receptor where the elevated IL-17RA 
expression is expected to take up most of the circulating serum IL-17 resulting in its 
reduced levels. In conclusion, we suggest that therapeutic inhibition of IL-17RA and 








CHAPTER 1  
 
INTRODUCTION 
1.1 Study background 
Interleukin (IL) is a form of cytokine that is released by leukocytes only but 
later found to be generated by many other body cells. They are particularly crucial in 
arousal of immune responses such as inflammation and also function in cell growth 
regulation, differentiation, activation and migration (Justiz Vaillant and Qurie, 2019). 
ILs are a large group of proteins that can induce several cells’ and tissues’ reactions 
by binding to strong affinity receptors on the cell surfaces. They may act on the cells 
in several ways which are autocrine, paracrine and endocrine actions (Abbas et al., 
2019). 
Acting as a metabolite of Th17, IL-17 has been implicated in the 
pathogenesis of autoimmune diseases such as SLE (Alessia Alunno et al., 2019). IL-
17 is active in epithelial and endothelial cells as well as plays an essential role in 
releasing IL-6 and other pro-inflammatory cytokines. Other than enhancing the 
activity of antigen-presenting cells (APCs), IL-17 also stimulated endothelial cell 
production of chemokines (Dhaouadi et al., 2018; Guerra et al., 2017). Other than IL-
17, IL-23 is deduced as one of pro-inflammatory cytokine that takes part in the 
pathogenesis of SLE. IL-23 is primarily synthesized by macrophage and dendritic 
cells to operate on T cells that enable the maintenance of IL-17 (Guerra et al., 2017). 
In this present study, the levels of IL-17, IL-23 and their receptors; namely 
IL-17RA and IL-23R were determined in SLE patients and healthy controls 
associated with serological parameters and SLEDAI-2K score to deduce the role of 
these interleukins and their receptors in the pathogenesis of SLE. 
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1.2 Problem statement 
SLE is known as a multifactorial disease, where genetic, endocrine, 
immunological and environmental factors influence the loss of immunological 
tolerance against self-antigens.  Recently, several studies showed the pathogenic role 
of T-helper type 17 (Th17) in SLE and the studies of specific therapeutic antibodies 
targeting IL-17 and IL-23 to aid the treatment of SLE patients. However, the 
participation of IL-17, IL-23 and their receptors in SLE pathogenesis remain unclear 
despite several studies has been done. This study aims to determine the levels of IL-
17, IL-23 and their receptors in SLE patients and healthy controls. Additionally, this 
study is to investigate the association of IL-17, IL-23 and their receptors with 
serological parameters such as C-reactive protein (CRP), antinuclear antibodies 
(ANA) and anti-double-stranded DNA (anti-dsDNA). This study is also to evaluate 
the association of IL-17, IL-23 and their receptors with disease activity (Systemic 
Lupus Erythematosus Disease Activity Index-2000; SLEDAI-2K score). 
1.3 Research question 










1.4 Objectives of the study 
1.4.1 General objective 
To determine the levels of IL-17, IL-23 and their receptors in SLE patients 
and their association with serological parameters and SLEDAI-2K scores. 
1.4.2 Specific objectives 
1. To determine the correlation of IL-17 and IL-23 levels between SLE 
patients and healthy controls. 
2. To determine the levels of IL-17RA and IL-23R within CD3⁺CD4⁺ T 
helper cells between SLE patients and healthy controls. 
3. To determine the association of IL-17, IL-23 and their receptors (IL-
17RA and IL-23R) levels between SLE patients and serological 
parameters (ANA and anti-dsDNA autoantibodies). 
4. To determine the association of IL-17, IL-23 and their receptors 
(IL17RA and IL23R) levels with CRP and SLEDAI-2K scores in SLE 
patients. 
1.5 Hypothesis 
1. IL-17 and IL-23 are associated with the presence of ANA, anti-dsDNA 
autoantibodies and CRP in SLE patients.  
2. IL-17RA and IL-23R are associated with the presence of ANA, anti-dsDNA 
autoantibodies and CRP in SLE patients.  
3. IL-17, IL-23 and their receptors (IL-17RA and IL-23R) are associated with 
disease activity based on SLEDAI-2K scores in SLE patients. 
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1.6 Importance and benefits of study 
1. No studies have been conducted in Malaysian or South-East Asian cohort of 
SLE patients in the determination of IL-17, IL-23 and their receptors (IL-
17RA and IL-23R) expression in SLE patients and their association with 
ANA, anti-dsDNA, CRP and SLEDAI-2K scores. 
2. There is no study has been conducted in Malaysia that focusing on specific 
races; eg. Malay within SLE patients in determining their interleukin receptor 
levels in SLE patients. 
3. Association of ANA, anti-dsDNA and CRP with IL-17, IL-23 and their 
receptors (IL-17RA and IL-23R) levels might serve as diagnostic markers for 




CHAPTER 2  
 
LITERATURE REVIEW 
2.1 Immune response and immunity 
Immunity is the capability of multicellular organisms to fight diseases, 
infections, harmful microorganisms, or other unsolicited biological invasions by 
having competent biological shield or defense and also possess adequate resistance to 
bypass autoimmune disease and allergy. The immune response is a mechanism 
whereby the body recognises and responds against viruses, bacteria and foreign 
substances. Apart from immunity to pathogenic microorganisms and its products, the 
immune response also acts as graft rejections, allergies and autoimmunity to self-
antigens. The human immune system has two primary constituents, each with 
different roles and functions; which are innate and adaptive immune responses 
(Labzin et al., 2018). 
2.1.1  Innate immunity 
Innate immune response, also called as native immunity symbolizes the 
primary line of defence against infections and plays diverse functions in health and 
disease, involving wound healing, tissue repairs and clearance of apoptotic cells and 
cellular debris. This primary defence response is crucial to promote the outgrowth 
arousal of adaptive immunity. Innate immunity functions can be classified into four 
distinct categories: detection, identification and removal of pathogens and 
contaminated cells, and, fourthly, activation of adaptive mechanism for a broad 
inflammatory response (Frizinsky et al., 2019).  
Acting as a non-specific defense mechanism, innate immunity acts promptly 
against the antigen’s appearance in the body. Major components of innate immunity 
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including physical barriers (e.g. skin, immune system cells attacking foreign cells, 
chemicals in the blood), phagocytic leukocytes (e.g. macrophages, neutrophils), 
antigen-presenting cells (APCs) (e.g. dendritic cells (DCs), natural killer (NK) cells, 
mast cells and ƴδ T cells) (Maruyama et al., 2011; Parnham and Rossi, 2019). 
2.1.2 Adaptive immunity 
Secondary immune response, mainly known as adaptive immunity, is a specific 
and acquired response which is established in response to specific foreign antigens 
exposure. Adaptive immunity can be sub-divided depending on the course immunity 
acquainted; naturally acquired through liability contact with the disease-causing agent 
and artificially acquired immunity which evolves through intentional actions such as 
vaccination. The anatomic sites of adaptive immunity are spleen, lymph nodes and 
mucosal-associated lymphoid tissue. Adaptive immunity is classified into the humoral 
immunity (i.e. antibodies by plasma cells) and cell-mediated immunity (i.e. T cell 
responses) (Pandit, 2017).  
Adaptive immunity grows slowly compared to innate immunity where it is 
distinguished by immunological memory resulting in more severe responses in 
subsequent exposures to the same antigen which triggered primary immune responses 
previously (Aribi, 2017). B cells are essential for adaptive immunity because they 
generate a range of antibodies that help to effectively eliminate antigens, including 
pathogens. B cells mature into plasma cells to produce immunoglobulins while T cells 
produce cytokines which can amplify or restrain inflammatory responses (Robert R.R. 
and David D.C., 2019). In fact, B cells perform an important function in the immune 
system by secreting cytokines and transmitting antigens (Ma et al., 2019). 
Autoimmune diseases induce abnormally low activation or overactive immune 
system function. Throughout instances of the overactive immune system, the 
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organisms fight and destroy its tissue such as by invading the joints, causing swelling 
and inflammation. Apart from B and T cells, neutrophils and macrophages are key 
components of diseases pathogenesis, since they play a vital role throughout inducing 
either pro- or anti-inflammatory reactions to the inflammatory site (Navegantes et al., 
2017). 
2.1.3 Immunological tolerance 
Tolerance is the suppression of an inflammatory response to a specific antigen. 
Immunological tolerance defends against bogus immune response to body 
constituents; is a condition of unresponsiveness of antigen-specific or tissue-specific 
immune response caused by prior exposure (Mathis and Benoist, 2010; Wu et al., 
2019). One of the key functions of the immune system is to identify self-antigens as 
non-threatening and produce active responses to the exclusion of non-self-antigens or 
foreign substances. Thus, the immune system is normally tolerant of self-antigens and 
typically does not damage owns’ cells and organs.  
Immunological tolerance involves a network of mechanisms that are central 
(by clonal deletion) and peripheral tolerance (by clonal ignorance, deletion and 
anergy) and transplantation tolerance involving suppressor T cells; a type of superior 
tolerance acting as an alternate mechanism other than clonal deletion and anergy (Wu 
et al., 2019; Mathis and Benoist, 2010). The immune system typically initiates 
immune responses promptly the following infection and shuts down immediately upon 
elimination of foreign invaders to avoid damage caused by excessive immune 
stimulation, which may lead to self-antigen reactions which trigger autoimmune 
diseases (Wu et al., 2019). 
To date, studies indicated that autophagy as an efficient way to control 
immune tolerance and evade over-activation of the immune response by attacking 
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several immune receptor and effector cells (Mocholi et al., 2018). Autophagy plays a 
vital role in both central and peripheral immunity, helps to prevent the deterioration of 
immune tolerance. Disorders such as autoimmune disease can arise when tolerance is 
lost as autoimmunity develops when the T or B cells identify themselves as foreign 
and strikes own tissues, inducing pathology. The pathological cause may be attributed 
to antibodies, inflammatory T cells (Th1/Th17) or antigen-antibody complexes 
(Kavathas P.B. et al., 2019). 
2.2 Systemic Lupus Erythematosus (SLE) 
SLE is a heterogeneous, multisystem autoimmune disorder that has a vast 
spectrum of effects on multiorgan and tissue involvements including skin, kidney, 
lung, brain, heart and joints (Qi et al., 2018; Mohan and Putterman, 2015). Numerous 
pro- and anti-inflammatory cytokines play pivotal pathogenic roles (Cavaillon, 2001). 
Thus, the main feature of SLE is the heterogenous autoantibodies group production 
against autoantigens in cells and the circulatory system (Qi et al., 2018). Essentially, 
inflammatory cytokines such as transforming growth factor-beta (TGF-β), IL-10, IL-6, 
interferon-γ (IFN-γ), IFN-α, B-cell activating factor (BAFF), IL-17 and IL-23 can be 
produced by both innate and adaptive immune cells to sustain exquisite immune 
homeostasis(Cavaillon, 2001). SLE undergoes distinct polymorphism and epigenetic 
changes caused by complex combination of genetic, epigenetic and environmental 
factors, leading to gene expression and function alterations in assorted molecules 
resulting in abnormal responses of T cells (Suarez-Fueyo et al., 2016).  
Immuno-pathogenesis of SLE is complex where the progression of disease 
affected by immune responses and components. Both immune responses are impaired 
in SLE patients resulting in self-tolerance deficit and production of autoantibodies, 
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associated with vital immunological alterations in SLE patients like T cell function, T 
regulatory (Treg) cells, cytokine production, epigenetic regulation as well as the 
balance of Th17 cells (Tsokos, 2011).  Aetiology of SLE is multifactorial and 
incorporates contribution from genetic, epigenetic, stochastic factors, hormonal, 
environmental and immuno-regulatory factors, which hinges on tolerance deficit and 
maintained lifelong autoantibodies production (Tsokos et al., 2016). Main SLE 
immuno-pathogenesis is self-tolerance breakdown where both innate and adaptive 
immunity is interlinked with each other through complements, immune complexes, 
cytokines and kinases of intracellular machinery (Pan et al., 2019). Immuno-
pathogenesis of SLE can be divided into two, which are dysregulation of DCs and 
neutrophils in innate immunity and both T and B cells impairment in adaptive 
immunity.  
In addition, to exhibit bizarre secretion of cytokine and cell signal 
transduction, T cells can also lead to improper recruitment and activation of B cells 
and DCs in inflammatory (Comte et al., 2015). Frauwirth et al., (2002) discovered T 
cells metabolism as activation of lymphocytes trigger cells growth, proliferation and 
differentiation which expand metabolic demand. A cellular metabolism disruption in 
SLE was first reported in T cell mitochondria, which give rise to the expanding of 
mitochondrial mass and CD4⁺ T cells in SLE (Frauwirth et al., 2002). A subtype of 
CD4⁺ T cells, T helper cells impairment is approximately associated with the 
manifestation and development of SLE, thus Th1/Th2 cells imbalance is deliberated as 
a vital part for SLE immuno-pathogenesis. Meanwhile, a subset of effector CD4⁺ T 
cells; Th17 cells are recognized with the capability to produce IL-17A, IL-17F and IL-
22, mediate inflammatory responses and engage in autoimmune diseases 
development. Beyond dysregulation of DCs, neutrophils and T cells as well as their 
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signalling abnormalities, a peculiar tolerance of central and peripheral B cells 
resulting a diverse of autoantibodies production by a vast amount of autoreactive B 
cells, leading to SLE immuno-pathogenesis (Morel, 2017). 
SLE has correlated with B cell polyclonal activation and autoantibodies 
formation that induces complex immune inflammation (Zamora et al., 2019). The 
immuno-pathogenesis of SLE was presented in Figure 2.1. The immature myeloid 
DCs (imDCs) undergo maturation and expressed abundance amount of costimulatory 
molecules (CD86, CD40 and MHC ll) and high levels of IL-6 and IL-12p70 which in 
turn mature DCs activates Th1 and Th2 cells by binding CD86 and CD40 to their 
ligand. Apart from inhibiting Treg proliferation, high production of IL-6 helps 
promotes Th17 differentiation which then IL-23 promotes the production of IL-17. 
Plasmacytoid dendritic cells (pDC) produced a high amount of IFN-α promoting B 
cell activation and B-T cells interaction enhancing the autoantibodies production. T 
cell leads to improper recruitment and activation of B cell in inflammation. 
Autoantibodies produced involved in forming autoantibodies immune complexes 
(ICs) which leads to inflammation. The improper activation of neutrophils released 
proteases which leads to tissue damage in SLE, while increases neutrophil 
extracellular trap (NET) released involved in pDCs activation in SLE, associated in 
inflammation. Sources: (Wu et al., 2016; Pan et al., 2019; van der Linden et al., 2018; 




Figure 2.1 Immuno-pathogenesis of SLE
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2.2.1 Epidemiology of SLE 
SLE affects women more frequently and the incidence peaks between 15 and 
44 years old (Fatoye et al., 2018; Rees et al., 2017; Carter et al., 2016). The 
prevalence of SLE is predicted 91.9/100,000 patients; women (89% cases) tends to be 
highest from a total of 41,804 patients diagnosed with SLE, according to Columbia 
National records (Fernandez-Avila et al., 2019), as compared to the study by Bae et 
al., (2019), the annual prevalence of SLE slightly increased from 21.25/100,000 
patients in 2005 to 35.45/100,000 patients in 2015 as recorded in National Health 
Insurance of South Korea (Bae et al., 2019).  
Being a multiracial country, Malaysia consists of three largest ethnic groups in 
Peninsular Malaysia which are Malays (69.3%), Chinese (22.8%) and Indians (6.9%), 
A change in the SLE epidemiology over time could be an outcome of age and ethnic 
diversity between population (Rees et al., 2016). 
2.2.2 Clinical features and manifestations of SLE 
SLE presents a range of features and manifestations from indolent to 
fulminant, depending on which part of the body is affected (Bartels and Muller, 2019) 
(Table 2.1). Disease assessment and diagnosis can be challenging as lupus imitates 
several other diseases; thus, it needs clinical and serologic assessment. As depicted by 
Cojocaru et al., (2011), there are multiple manifestations in SLE namely 
constitutional, musculoskeletal, dermatological, renal, neuropsychiatric, pulmonary, 
gastrointestinal, cardiac, vascular, ocular, obstetric, endocrine and hematologic 
manifestations (Cojocaru et al., 2011).  
SLE patients may show diverse systemic symptoms such as fever, headache, 
arthralgias, myalgias, malaise, food aversion and weight loss. Fever, nonspecific 
fatigue, weight changes and arthralgia are the prevailing signs for recurrent active 
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SLE or new SLE cases. Musculoskeletal manifestation is common as patients 
regularly seek medical attention for joint pains as osteonecrosis, myopathy, arthritis 
and arthralgia. A meta-analysis on clinical manifestations of childhood- and adult-
onset SLE showed that sicca and Raynaud’s phenomenon are more common in adults 
than adolescents and children SLE (Livingston et al., 2011). On the other hand, fever, 
haemolytic anaemia, ulcers or mucocutaneous involvement, malar rash, proteinuria, 
renal involvement, urinary cellular cast, lymphadenopathy and thrombocytopenia are 
more common in childhood-onset SLE (Bartels and Muller, 2019). The common 
clinical features of SLE are explained in Table 2.1. 
 
Table 2.1 Common clinical features of SLE 
 
Clinical features Clinical manifestations 
Unexplained fever 
• Acting as an early sign of SLE with low-grade fever 
(36.9˚C to 38.3˚C) 
• Fever occurs intermittently 
Headache 
• Inflammation in the brain causes headaches, fatigue, 
vision problems, seizures or behaviour changes 
• May also be triggered by vasculitis (blood vessels 
swelling or inflammation) 
Rash/ lesions 
• Butterfly-shaped rash on the bridge of the nose and 
both cheeks 
• May appear abruptly or occur after sunlight exposure 
(sensitive to sunlight) 
Hair loss 
• Thinning hair triggered by skin and scalp 
inflammation 
• Patients might also have facial thinning, brows, 
eyelashes and other body hair loss due to hair fragility 
Dry mouth and eyes 
• Gritty and dry eyes and mouth due to malfunction of 
salivary glands  
• In some instances, women may also feel the dryness of 
the skin and vagina 
Swollen and painful 
joints 
• Inflammation may cause stiffness, pain and noticeable 
swelling of the joints, especially in the morning 




2.2.3 Laboratory characteristics of SLE 
Early diagnosis and treatment are crucial in SLE. However, medical symptoms 
of SLE typically resemble other autoimmune diseases and thus serological measures 
are required to validate the diagnosis. These laboratory tests include ANA test, anti-
dsDNA, CRP level and anti-ENA as summarised in Table 2.2.  
 
Table 2.2 Laboratory tests for screening and diagnosis of SLE 
 
Laboratory tests Explanations 
Antinuclear 
antibody (ANA) 
ANA test is widely used to measure autoantibodies that target the 
nucleus of the cells or ‘control’ area. ANA is a main serological 
test to indicate the presence of autoimmune diseases involving 
multiple organs systemically. ANAs are found in over 95% of 
SLE patients in elevated titres (Isenberg et al., 2019). 
Nevertheless, due to its low positive predictive value, a positive 
ANA test on its own is inadequate to diagnose SLE or other 
autoimmune diseases. Therefore, a corresponding serological 
analysis such as anti-dsDNA and CRP levels are required.  
 
Testing by immunofluorescence on HEp-2 cells, ANA at a titre 





Anti-dsDNA autoantibodies mistakenly target and attack the 
body's genetic material, causing inflammation and tissue damage. 
Anti-dsDNA autoantibodies in an immunoassay with 
demonstrated > 60 (IU/ml) was considered positive, while 





CRP is formed in the liver and a proxy of systemic inflammation. 
CRP is an acute reactant phase which indicates that its 
concentrations rise in response to inflammation.  
 
Normal CRP levels are below 3.0 mg/l, while a high-sensitivity 
CRP test can detect levels below 10.0 mg/l. An inflammatory 




An anti-ENA screen is usually prescribed following a positive 
result in an antinuclear antibody (ANA) test. Anti-ENA screen 
determines the levels of seven different autoantibodies including 





2.2.4 Clinical evaluation of SLE disease activity 
SLE diagnosis criteria developed by American College of Rheumatology 
(ACR) state that if an individual encountered at least four out of 11 symptoms with no 
other explanation behind them, physicians can use as a reference to decide whether a 
patient with symptoms have lupus. Some of the symptoms are discoid and malar rash, 
mouth or nose sores, arthritis, kidney problem (e.g. blood or protein present in urine), 
pleuritis or pericarditis, neurologic problem (e.g. psychosis, strokes, or seizures), and 
abnormal blood tests (such as anaemia, abnormality of specific antibodies; e.g. anti-
dsDNA, or positive ANA result) (Rheumatology, 2019). When patients meet the ACR 
criteria as listed in Table 2.3, a set of blood tests will be conducted to validate the 
diagnosis where if ANA is positive, more specific tests including anti-dsDNA and 





Table 2.3 ACR criteria for the classification of SLE 
Criterion Definition 
Malar rash 
Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
Discoid rash 
Erythematosus raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions 
Photosensitivity 
Skin rash as a result of unusual reaction to sunlight, by patient 
history or physician observation 
Oral ulcers 




Involving 2 or more peripheral joints, characterized by tenderness, 
swelling or effusion 
Pleuritis or 
Pericarditis 
Pleuritis -- a convincing history of pleuritic pain or rubbing heard 
by a physician or evidence of pleural effusion 
Or 
Pericarditis -- documented by electrocardiogram or rub or evidence 
of pericardial effusion 
Renal disorder 
Persistent proteinuria > 0.5 grams per day or > than 3+ if 
quantitation not performed 
Or 




Seizures – in the absence of offending drugs or known metabolic 
derangements; e.g., uraemia, ketoacidosis, or electrolyte imbalance 
Or 
Psychosis – in the absence of offending drugs or known metabolic 
derangements, e.g., uraemia, ketoacidosis, or electrolyte imbalance 
Hematologic 
disorder 
Haemolytic anaemia--with reticulocytosis 
Or 
Leukopenia --< 4,000/mm³ on ≥ 2 occasions 
Or 
Lymphopenia --< 1,500/mm³ on ≥ 2 occasions 
Or 




Anti-DNA: antibody to native DNA in abnormal titre 
Or 
Anti-Sm: the presence of antibody to Sm nuclear antigen 
Or 
A positive finding of antiphospholipid antibodies on: 
1. An abnormal serum level of IgG OR IgM anti-cardiolipin 
antibodies, 
2. A positive test result for lupus anticoagulant using a 
standard method, or 
3. A false-positive test result for at least 6 months confirmed 
by Treponema pallidum immobilization or fluorescent 




An abnormal titre of antinuclear antibody by immunofluorescence 




To date, 2019 SLE European League Against Rheumatism/American College 
of Rheumatology (EULAR/ACR) classification criteria has been developed for SLE 
(Aringer et al., 2019). Compared to previous criteria, SLE ACR 1997 (Hochberg, 
1997) and Systemic Lupus International Collaborating Clinics (SLICC) 2012 (Petri et 
al., 2012), EULAR/ACR criteria have been developed to find a better compromise of 
specificity and sensitivity.  
2019 EULAR/ACR is designed to enhance the sensitivity and specificity of 
SLE classifications, which have been suggested for usage in SLE research studies and 
trials rather than for diagnostic purposes. It is advised that the involvement of positive 
ANA at a titer 1:80 or higher by immunofluorescence (IFA) as an entry criterion for 
classification of SLE (Rodrigues Fonseca et al., 2019) and refining the SLICC 2012, 
requiring the present of at least 1 immunologic criterion (Aringer et al., 2019). 
Measurement of SLE disease development or activity remains challenging due 
to the dynamic multi-system of lupus complexity. However, it is essential for the 
assessment of treatment outcomes as well as response to novel therapies in clinical 
trials. There are two main protocols used to measure SLE disease activity: (1) Global 
Score System for comprehensive activity measurement as well as individual organ 
assessment such as Systemic Lupus Activity Measure (SLAM), European Consensus 
Lupus Activity Measurements (ECLAM) and Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI); (2) British Isles Lupus Assessment Group Index (BILAG) 
is the System Assessment Scale to assess particular disease activity in specific organs 
(Fernando and Isenberg, 2005).  
SLEDAI is a global index for the measurement of lupus disease occurrence in 
the intervening 10 days. SLEDAI score comprises of 24 weighted medical and 
experimental factors in nine organ systems. The descriptor scores vary from 1 to 8 and 
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the total possible score for all 24 descriptors is 105. Currently, the 30-day continuation 
of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) is 
proportionate to the initial 10-day version (Mikdashi and Nived, 2015; Touma et al., 
2010). SLEDAI-2K descriptors are listed as present or absent, each has a weighted 
ranking and the total score of SLEDAI-2K is the total of all 24 descriptor scores, 
allowing the detection of persistent active disease in mucous membrane ulcers, 
proteinuria, alopecia and rash. The total score of SLEDAI-2K ranging within 0 and 
105. The decision-making to treat feasibility of therapy initiation in more than 50 per 
cent cases are affected by a deemed medically significant, a score of 6 and meaningful 
change and progress is best defined as a SLEDAI-2K reduction by 4. 
2.3 Cytokines 
The intermediary intracellular protein signals of the immune system are 
generally known as cytokines; consisting of interleukins (produced by one leukocyte 
to modulate the activities of another leukocyte), chemokines (for chemotaxis of cells), 
interferons (involved in antiviral reactions), lymphokines, monokines and tumour 
necrosis factor (TNF) (Kindt et al., 2007).  Cytokines are formed by a wide range of 
cells including immune cells such as T and B cells, macrophages, mast cells, 
granulocytes, stromal cells, endothelial cells and fibroblasts (Lackie and O'Callaghan, 
2010). Cytokines play vital roles in the differentiation, maturation and activation of 
numerous immune cells, and to mount a potent immune response (Zhang and An, 
2007). At such, overproduction of pro-inflammatory cytokines may cause or 
exacerbate autoimmune diseases including SLE (Oppenheim, 2020). 
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2.3.1 Types of inflammatory cytokines 
Pro-inflammatory cytokines such as IL-1, IL-6, IL-12, TNF-α and IFN-γ are 
produced by immune cells such as T helper (Th) cells and macrophages. Pro-
inflammatory cytokines could render the infection worse by inducing fatigue, tissue 
damage and in certain instances, causing shock and death (Dinarello, 2000). 
Meanwhile, IL-4, IL-10, IL-13, IFN-α and transforming growth factor-beta (TGFβ) 
are anti-inflammatory cytokines essential for the suppression and resolution of 
diseases (Chen et al., 2019; Murray et al., 2014; Cavaillon, 2001). 
2.3.2 Interleukins 
2.3.2(a) Interleukin-17 (IL-17 or IL-17A) 
IL-17 is a potent pro-inflammatory cytokine that mediates protective immunity 
(Zenobia and Hajishengallis, 2015) and acts as a host defence against microbial 
pathogens (Chen and Kolls, 2017). The family members of IL-17 consist of IL-17A 
(also known as IL-17), IL-17B, IL-17C, IL-17D, IL-17E and IL-17F (Sakkas and 
Bogdanos, 2017). IL-17 is mainly produced by CD4⁺ T helper 17 (Th17) cells (Jin and 
Dong, 2013; Lee et al., 2015) in response to their stimulation by IL-23 produced by 
macrophages and dendritic cells (DCs) (Iwakura and Ishigame, 2006; Suzuki et al., 
2014). IL-17 is also produced by CD8+ T cells, natural Th17 cells, innate lymphoid 
cells (ILCs), and natural killer T (NKT) cells as listed in Table 2.4 (Coquet et al., 
2008; Gaffen et al., 2014; Korn et al., 2009; Liang et al., 2015; Marks et al., 2009). 
The activation and maturation of Th17 cells rely on adequate T cell receptor (TCR) 
expression, costimulatory molecules and cytokines such as IL-6 and IL-21, which play 





Table 2.4 Sources, production sites and mode of IL-17 production 
 
Sources Production sites Mode of IL-17 production Reference 
CD4+ T cells 
Thymus/peripheral 
lymphoid tissues 
Upon activation and expansion, CD4+ T cells develop into CD4⁺ Th17 
cells with the production of IL-6 by DCs that induce IL-17 production 
(Korn et al., 2009) 
CD8+ T cells 
Thymus/peripheral 
lymphoid tissues 
CD8+ T cells develop into Tc17 cells, inducing IL-17 production. In Tc17 
cells maturation, IL-23 is required for their expansion and maintenance 




Skin and mucosa 
Both transcription factors, RORƴt5 and RORα6 are expressed by Th17 
cells, to produce IL-17 and also express the production of IL-23R 
(Marks et al., 2009) 
Thymus 
Similar to adaptive Th17, nTh17 cells also develop in the thymus and 
induce IL-17 production 
(Gaffen et al., 2014) 
Innate lymphoid 
cells (ILCs) 
Gut and skin Produce IL-17 in response to inflammatory cytokines and stress 
NKT Thymus and liver 
NKT cell subsets are categorized based on CD4 and NK1.1 expression, 
and tissue of origin. 
Activated CD4-NK1.1- NKT cells produce high levels of IL-17 




IL-17 is critical for the protection against extracellular bacteria, protozoa and 
fungal infections at mucosal and epithelial barriers (Matsuzaki and Umemura, 2018). 
IL-17 signals through a heterodimeric receptor complex, IL-17RA and IL-17RC, 
where IL-17RA is found ubiquitously but can only signal in the presence of IL-17RC 
(Astry et al., 2015).  
IL-17R, a type I surface receptor, consists of IL-17RA (mainly known as IL-
17R), IL-17RB, IL-17RC, IL-17RD and IL-17RE (Xu and Cao, 2010). IL-17R 
interacts with IL-17 and activates the signalling cascades leading to the induction of 
chemokine production and release to recruit immune cells to the site of inflammation. 
However, this phenomenon also contributes to the pathogenesis of autoimmune 
diseases such as rheumatoid arthritis (RA) and spondylarthritis (SpA) where IL-17 
directly aggravates the inflammation site by stimulating immune cells to produce pro-
inflammatory cytokines, chemokines and other inflammatory mediators including 
nitric oxide (NO), prostaglandins and matrix metalloproteinases (MMPs) (Lubberts, 
2015). Aberrant production of IL-17 has also been implicated in SLE, RA, 
inflammatory bowel disease (IBD) and psoriasis (Abdel Galil et al., 2015; Jin and 
Dong, 2013).  
2.3.2(b) Interleukin-23 (IL-23)  
IL-23 (p19/p40) is an important cytokine in the development, expansion and 
proliferation of Th17 cells (Du et al., 2014) where it is produced by inflammatory 
myeloid DCs (mDCs), monocyte-derived DCs (Mo-DCs), intestinal macrophages, 
eosinophils and epithelial cells as listed in Table 2.5 (Garg et al., 2015; Guerra et al., 
2017; Krause et al., 2015; Macho-Fernandez et al., 2015; Shi et al., 2015). IL-23 is 
involved in the development and maintenance of autoimmune inflammation (Tang et 
al., 2012; Teng et al., 2015). IL-23 belongs to IL-12 cytokine family which includes 
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IL-12, IL-23, IL-27 and IL-35; IL-23 induces memory T cells to produce interferon-γ 
(IFN-γ) and potently enhances the expansion of Th17 cells for the production of IL-17 





Table 2.5 Sources, production sites and mode of IL-23 production 
 
Sources Production sites Mode of IL-23 production Reference 
Inflammatory myeloid 
dendritic cells (imDCs) 
Bone marrow 
gp120-treated with mDCs induced production of IL-23, which 
then upregulated the suppressor of cytokine signalling 1 
(SOCS1) protein in T cells 




Treatment with PGE2 has been demonstrated to act in a cAMP-
dependent manner to elevate IL-23 production in human Mo-
DCs  
(Shi et al., 2015) 
Intestinal macrophages Intestine 
As IL-10 is an anti-inflammatory cytokine which limits 
mucosal immune responses, the addition of IL-10 reduces IL-
23 production by intestinal macrophages in mice 
(Krause et al., 
2015) 
Eosinophils Lung 
Confocal microscopy on cells obtained by bronchoalveolar 
lavage 8- and 54-hours post-infection with Aspergillus 
fumigatus were performed to confirm that eosinophils produced 
IL-23p19 and IL-17A in mice 




(Intestinal epithelial cells) 
Lymphotoxin beta receptor (LTβR) signalling in intestinal 
epithelial cells promotes self-repair after mucosal damage 
(wound healing) and essential for epithelial IL-23 production  
(Macho-






As a heterodimer, IL-23 is composed of a p19 and p40 subunit, the latter being 
shared with IL-12 (p35/p40) (Arnold et al., 2016; Astry et al., 2015; Tang et al., 
2012). p19 expression is produced by antigen-presenting cells (APCs), T cells and 
endothelial cells, while p40 is particularly limited to APCs e.g. DCs, monocytes and 
macrophages (Tang et al., 2012). IL-23 forms a disulphide-linked complex with p19 
and p40 secreted by activated macrophages and DCs in peripheral tissues e.g. lung, 
skin and intestinal mucosa where the synthesis of both p40 and p19 subunits are 
within the same cell that produces IL-23 (Tang et al., 2012). However, both IL-23 and 
IL-12 have distinct functions and their production in response to pathogens are also 
differently regulated where IL-23 stimulates Th17 to produce IL-17, while IL-12 
promotes Th1 response (Lyakh et al., 2008). 
The IL-23 receptor, IL-23R, is found on activated memory T cells, NKT cells, 
macrophages, and DCs (AlFadhli, 2013; Korn et al., 2009). Naïve T cells do not 
express IL-23R, while the receptor is expressed on activated Th17 cells (Astry et al., 
2015). Binding of IL-23 with its receptor complex activates STAT3 signalling in Th17 
cells that induce Th17 differentiation to gain effector functions including expression 
of pro-inflammatory cytokines IL-17 and IFN-γ (Bedoya et al., 2013; Lee et al., 
2017). IL-23 is involved in the onset of several autoimmune inflammatory diseases 
such as psoriasis, colitis, gastritis, and arthritis (Fotiadou et al., 2018; Tang et al., 
2012), and high serum levels of IL-23 have been demonstrated in patients with SLE 
(Du et al., 2014). 
2.3.3 IL-23/IL-17 axis in autoimmunity 
The initial steps of naïve CD4⁺ T cells differentiation into IL-17 producing 
cells does not require IL-23, however, IL-23 plays an important role in stabilizing the 
phenotypic features of the Th17 lineage. IL-23 is important in the expansion and 
